In conclusion, this study demonstrated that hepatocyte-derived FGL1 played critical regulatory roles in the liver immune microenvironment and accounted for liver metastasis and tumor growth by inhibiting CD8+ T and NK cell functions via the receptor LAG-3, providing a new strategy for liver cancer immunotherapy. Here, CD8A is linked to neoplasm.